31 May 2026
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Todd Trattner Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Jing Cao | Latham & Watkins LLP | Associate | Not stated | Not stated |
| William Lane | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.30bn (US$1.3 billion)
- What the figure measures
- Facility amount
- Client
- Apogee Therapeutics, Inc.Borrower
- Counterparties
- Blackstone Life Sciences (Lenders)